The Region Is Modernizing Simultaneously. That Changes the Strategy.
2024–2026 · Pharmaceuticals, Medical Devices, Veterinary & Personal Care · Latin America & The Caribbean
The regulatory changes that took effect across Latin America and the Caribbean between 2024 and 2026 are not isolated events. Panama accelerated approvals for HSC products. Peru introduced a 45-day expedited pathway for specialty treatments. Jamaica digitized its entire submission system. Nicaragua stood up a new regulatory authority from the ground up. Regional harmonization frameworks advanced in Central America and the Caribbean simultaneously.
Taken together, these developments represent the most meaningful regulatory modernization the region has seen in over a decade. Understanding them country by country is necessary. Understanding them as a pattern is what drives strategy.
The Common Thread
Across markets, the reforms share a structural logic: reduce friction for products that already carry international regulatory credibility, build digital infrastructure to replace paper-based processes, and align local standards with global frameworks.
Panama and Peru both introduced HSC pathways that give FDA-, EMA-, and WHO-listed authority approvals direct weight in local review. Jamaica’s digital platform was built with enhanced cooperation mechanisms with US, UK, and EU authorities. Nicaragua’s ANRS is developing under WHO technical assistance and PAHO collaboration. The direction is consistent even where the pace differs.
For companies with strong international regulatory portfolios, this shift is material. Approvals that previously provided no procedural advantage in Latin American markets now open accelerated pathways in multiple countries simultaneously.
The Harmonization Layer
Beyond individual country reforms, three regional mechanisms are actively developing.
The Latin American and Caribbean Medicines Agency , AMLAC , was established by declaration in April 2023, with Colombia’s INVIMA, Cuba’s CECMED, and Mexico’s COFEPRIS as founding members, and Argentina, Brazil, and Chile in supporting roles. Framework and governance discussions continued through 2025. An operational launch remains a longer-term development to monitor rather than a near-term planning factor , but the direction of travel is toward regional coordination that could eventually allow single submissions across member markets.
The Central American Joint Mechanism is already operational for chemical synthesis drugs, with Guatemala, El Salvador, and Honduras as active participants and Nicaragua, Costa Rica, and Panama in various stages of development. A single technical review process with less than three months of processing time is the current standard. Expansion to biologics is under consideration. PAHO support has been enhanced. For companies with Central American portfolios, this mechanism is not theoretical , it is a live coordination tool.
The Caribbean Regulatory System, managed by the Caribbean Public Health Agency across CARICOM member states, continues to develop its reliance mechanisms and digital submission platforms. Enhanced capacity and expanded reference authority acceptance characterize the current development phase.
The companies gaining ground in this region are not the ones reacting to individual regulatory changes. They are the ones reading the pattern and sequencing accordingly.
What Simultaneous Modernization Means Operationally
When multiple markets reform at the same time, the opportunity cost of a reactive posture compounds. A company that waits for each change to settle before engaging misses the early-mover window in every market. A company that tracks the pattern and moves ahead of stabilization builds a portfolio position that later entrants can’t easily replicate.
It also means that the internal infrastructure required to operate across these markets is changing. Digital submission readiness, CTD-format documentation, and reference authority approvals are no longer differentiators for sophisticated entrants , they are table stakes across an increasing number of markets. Companies that haven’t built these capabilities aren’t just slower. They are entirely locked out of expedited pathways.
Digital Transformation Across the Region
The platform developments extend beyond the four markets covered in detail. Puerto Rico has enhanced its electronic registration capabilities and introduced virtual manufacturing authorization processes. Costa Rica launched an online portal for biomedical equipment registration covering Class II through IV devices. Nicaragua’s Karplus platform handles medical device submissions digitally from the outset.
Post-market surveillance requirements are also evolving. The Dominican Republic’s Decree 284-21 modernized adverse event reporting with digital platforms and enhanced manufacturer obligations. Costa Rica strengthened its pharmacovigilance reporting with online submission and international alignment to WHO standards.
The administrative burden of compliance across the region is not disappearing , it is shifting from paper-based opacity to digital infrastructure that rewards preparation.
The Sequencing Question
For companies evaluating or actively managing a Latin American and Caribbean portfolio, the reforms of 2024 through 2026 raise a specific strategic question: given where each market is in its modernization cycle, what is the right order of entry, and which approvals should be secured first to maximize their value across multiple pathways simultaneously?
Panama’s HSC pathway and Peru’s Law 32319 both recognize the same set of reference authorities. A product with FDA approval is an asset in both markets , and in Jamaica’s fast-track system. The sequencing logic for a company with that approval looks very different from the logic for a company that is still building its international regulatory portfolio.
That calculation is different for every portfolio. But the underlying principle is consistent: in a region modernizing at the same time, regulatory strategy is no longer a market-by-market exercise. It is a regional one.
Rebexa monitors regulatory developments across 16+ markets in real time. If you have questions about how these regional reforms affect your market access strategy, contact us.